Literature DB >> 24008346

Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.

M Victoria Recouvreux1, Lara Lapyckyj, M Andrea Camilletti, M Clara Guida, Ana Ornstein, Daniel B Rifkin, Damasia Becu-Villalobos, Graciela Díaz-Torga.   

Abstract

Dopamine and estradiol interact in the regulation of lactotroph cell proliferation and prolactin secretion. Ablation of the dopamine D2 receptor gene (Drd2(-/-)) in mice leads to a sexually dimorphic phenotype of hyperprolactinemia and pituitary hyperplasia, which is stronger in females. TGF-β1 is a known inhibitor of lactotroph proliferation. TGF-β1 is regulated by dopamine and estradiol, and it is usually down-regulated in prolactinoma experimental models. To understand the role of TGF-β1 in the gender-specific development of prolactinomas in Drd2(-/-) mice, we compared the expression of different components of the pituitary TGF-β1 system, including active cytokine content, latent TGF-β-binding protein isoforms, and possible local TGF-β1 activators, in males and females in this model. Furthermore, we evaluated the effects of dopamine and estradiol administration to elucidate their role in TGF-β1 system regulation. The expression of active TGF-β1, latent TGF-β-binding protein isoforms, and several putative TGF-β1 activators evaluated was higher in male than in female mouse pituitary glands. However, Drd2(-/-) female mice were more sensitive to the decrease in active TGF-β1 content, as reflected by the down-regulation of TGF-β1 target genes. Estrogen and dopamine caused differential regulation of several components of the TGF-β1 system. In particular, we found sex- and genotype- dependent regulation of active TGF-β1 content and a similar expression pattern for 2 of the putative TGF-β1 activators, thrombospondin-1 and kallikrein-1, suggesting that these proteins could mediate TGF-β1 activation elicited by dopamine and estradiol. Our results indicate that (1) the loss of dopaminergic tone affects the pituitary TGF-β1 system more strongly in females than in males, (2) males express higher levels of pituitary TGF-β1 system components including active cytokine, and (3) estradiol negatively controls most of the components of the system. Because TGF-β1 inhibits lactotroph proliferation, we propose that the higher levels of the TGF-β1 system in males could protect or delay the development of prolactinomas in Drd2(-/-) male mice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24008346      PMCID: PMC3800752          DOI: 10.1210/en.2013-1433

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  48 in total

Review 1.  Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability.

Authors:  Daniel B Rifkin
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

2.  Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes.

Authors:  D K Sarkar; K Chaturvedi; S Oomizu; N I Boyadjieva; C P Chen
Journal:  Endocrinology       Date:  2005-06-16       Impact factor: 4.736

3.  Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.

Authors:  Laurence Levy; Caroline S Hill
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas.

Authors:  Weiping Liu; Yoshihito Matsumoto; Masaki Okada; Keisuke Miyake; Katsuzo Kunishio; Nobuyuki Kawai; Takashi Tamiya; Seigo Nagao
Journal:  J Med Invest       Date:  2005-08

5.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Authors:  J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

6.  Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.

Authors:  Jian Gong; Yunge Zhao; Rana Abdel-Fattah; Samson Amos; Aizhen Xiao; M Beatriz S Lopes; Isa M Hussaini; Edward R Laws
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors.

Authors:  Abby J Sarkar; Kirti Chaturvedi; Cui Ping Chen; Dipak K Sarkar
Journal:  J Endocrinol       Date:  2007-02       Impact factor: 4.286

8.  Estradiol-induced synaptic remodeling of tyrosine hydroxylase immunopositive neurons in the rat arcuate nucleus.

Authors:  Eszter Csakvari; Anita Kurunczi; Zsofia Hoyk; Andrea Gyenes; Frederick Naftolin; Arpad Parducz
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

9.  Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors.

Authors:  Keiji Yoshinaga; Hiroto Obata; Vladimir Jurukovski; Roberta Mazzieri; Yan Chen; Lior Zilberberg; David Huso; Jonathan Melamed; Petra Prijatelj; Vesna Todorovic; Branka Dabovic; Daniel B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-20       Impact factor: 11.205

Review 10.  Sex differences in pharmacokinetics and pharmacodynamics.

Authors:  Offie P Soldin; Donald R Mattison
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more
  3 in total

Review 1.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

2.  MMP-14 and TGFβ-1 methylation in pituitary adenomas.

Authors:  Kornelija Ruskyte; Rasa Liutkevicienė; Alvita Vilkeviciute; Paulina Vaitkiene; Indre Valiulytė; Brigita Glebauskiene; Loresa Kriauciuniene; Dalia Zaliuniene
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

Review 3.  Pituitary Hyperplasia, Hormonal Changes and Prolactinoma Development in Males Exposed to Estrogens-An Insight From Translational Studies.

Authors:  Branka Šošić-Jurjević; Vladimir Ajdžanović; Dragana Miljić; Svetlana Trifunović; Branko Filipović; Sanja Stanković; Sergey Bolevich; Vladimir Jakovljević; Verica Milošević
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.